Concord Drugs Limited (BOM:538965)

Concord Drugs Income Statement

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Operating Revenue	471.58	452.45	449.25	520.81	589.57	513.57
Other Revenue	0	0	-	-	0.86	0.87
Revenue	471.58	452.45	449.25	520.81	590.43	514.44
Revenue Growth (YoY)	-1.00%	0.71%	-13.74%	-11.79%	14.77%	0.03%
Cost of Revenue	376.28	352.3	337.33	415.96	425.7	434.11
Gross Profit	95.31	100.14	111.92	104.85	164.73	80.33
Selling, General & Admin	40.62	46.35	60.76	49.19	48.91	37.55
Other Operating Expenses	11.5	12.45	10.73	9.94	7.55	9.71
Operating Expenses	66.72	73.11	87.04	75.38	125.59	60.92
Operating Income	28.58	27.04	24.87	29.46	39.14	19.41
Interest Expense	-20.64	-20.27	-18.17	-16.34	-15.79	-13.31
Interest & Investment Income	-	-	0.09	0.06	0.12	0.08
Other Non Operating Income (Expenses)	0.14	0.15	-0.5	-0.7	-0.99	-0.89
EBT Excluding Unusual Items	8.09	6.91	6.29	12.49	22.48	5.29
Other Unusual Items	-	-	-	-	-	37.63
Pretax Income	8.09	6.91	6.29	12.49	22.48	42.92
Income Tax Expense	3.82	3.55	1.57	2.63	6.54	10.1
Net Income	4.27	3.36	4.72	9.86	15.94	32.82
Net Income to Common	4.27	3.36	4.72	9.86	15.94	32.82
Net Income Growth	4536.96%	-28.83%	-52.06%	-38.19%	-51.42%	899.60%
Shares Outstanding (Basic)	10	10	10	9	9	9
Shares Outstanding (Diluted)	10	10	10	9	9	9
Shares Change (YoY)	0.53%	-1.12%	7.35%	6.53%	-	-
EPS (Basic)	0.42	0.34	0.47	1.06	1.82	3.75
EPS (Diluted)	0.42	0.34	0.47	1.06	1.82	3.75
EPS Growth	4512.88%	-27.66%	-55.57%	-41.87%	-51.47%	898.78%
Free Cash Flow	-	13.89	-2.26	8.06	-16.82	-36.74
Free Cash Flow Per Share	-	1.41	-0.23	0.87	-1.92	-4.20
Gross Margin	20.21%	22.13%	24.91%	20.13%	27.90%	15.62%
Operating Margin	6.06%	5.98%	5.54%	5.66%	6.63%	3.77%
Profit Margin	0.91%	0.74%	1.05%	1.89%	2.70%	6.38%
Free Cash Flow Margin	-	3.07%	-0.50%	1.55%	-2.85%	-7.14%
EBITDA	42.58	41.34	40.43	45.72	56.79	33.06
EBITDA Margin	9.03%	9.14%	9.00%	8.78%	9.62%	6.43%
D&A For EBITDA	14	14.31	15.55	16.26	17.65	13.65
EBIT	28.58	27.04	24.87	29.46	39.14	19.41
EBIT Margin	6.06%	5.98%	5.54%	5.66%	6.63%	3.77%
Effective Tax Rate	47.26%	51.37%	24.88%	21.09%	29.08%	23.54%
Revenue as Reported	471.73	452.59	449.34	520.89	590.57	514.52

Source: S&P Global Market Intelligence. Standard template. Financial Sources.